Skip to main content
JNJ
NYSE Life Sciences

强生公司的Icotyde显示出持久的皮肤清除和有利的安全性，在一年皮肤病试验中

feedReported by Reuters
Sentiment info
Positive
Importance info
7
Price
$240.655
Mkt Cap
$579.46B
52W Low
$141.5
52W High
$251.71
Market data snapshot near publication time

summarizeSummary

强生公司宣布其每日一次的药丸Icotyde (icotrokinra)用于斑块性皮肤病的一年临床试验结果为正。数据证实了持久的皮肤清除和有利的安全性，强化了该药物对患者的潜在疗效和安全性。这一积极的发展加强了强生公司的药品管道和其在皮肤病学市场的地位。虽然对该产品来说很重要，但对于像强生公司这样规模的公司来说，这则新闻代表着一个适度的正面催化剂，而不是一个重要的股票移动事件。投资者将继续监测Icotyde的监管进展和商业启动表现。

在该公告发布时，JNJ的交易价格为$240.66，交易所为NYSE，所属行业为Life Sciences，市值约为$5794.6亿。 52周交易区间为$141.50至$251.71。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed JNJ - Latest Insights

JNJ
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Imaavy Secures FDA Priority Review for Rare Blood Disorder
Sentiment: Positive
View Wiseek Article
JNJ
Apr 24, 2026, 9:12 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J Acquires Atraverse Medical to Bolster Cardiac Device Portfolio
Sentiment: Positive
View Wiseek Article
JNJ
Apr 22, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
J&J Reports Strong Q1 Operational Sales Growth, Raises Dividend Amidst Talc Litigation Challenges and Increased Net Debt
Sentiment: Neutral
View Wiseek Article
JNJ
Apr 22, 2026, 10:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Nipocalimab-aahu Phase 3 Study Shows Sustained Improvements for Autoantibody Disease
Sentiment: Positive
View Wiseek Article
JNJ
Apr 17, 2026, 6:47 PM EDT
Source: Reuters
Importance Score:
8
Judge Rejects Bayer's Bid to Block J&J's Multibillion-Dollar Prostate Cancer Drug Claims
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 4:07 PM EDT
Source: Wiseek News
Importance Score:
8
J&J Talc Bankruptcy Plan Voided by Court, Reopening Lawsuits; Q1 Revenue Hits $24B, Guidance Raised
Sentiment: Negative
View Wiseek Article
JNJ
Apr 14, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Johnson & Johnson Reports Strong Q1, Raises 2026 Guidance, and Increases Dividend for 64th Consecutive Year
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 6:20 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Innovative Medicine Sales Growth Fueled by Darzalex, Carvykti, Erleada, Rybrevant, Tremfya, and Spravato
Sentiment: Positive
View Wiseek Article
JNJ
Apr 13, 2026, 12:44 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Johnson & Johnson Q1 Sales Expected Up, Profit Down Ahead of Earnings Report
Sentiment: Neutral
View Wiseek Article
JNJ
Mar 30, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
J&J Secures $500M R&D Pact for JNJ-4804, Reports 71% ORR for JNJ-1900 in NSCLC Trial
Sentiment: Positive
View Wiseek Article